



- (51) **International Patent Classification:**
G01N 33/50 (2006.01) *G01N 33/58* (2006.01)
G01N 33/574 (2006.01)
- (21) **International Application Number:**
PCT/US2022/011606
- (22) **International Filing Date:**
07 January 2022 (07.01.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/135,711 10 January 2021 (10.01.2021) US
- (71) **Applicant: KITE PHARMA, INC.** [US/US]; 2400 Broadway, Santa Monica, CA 90404 (US).
- (72) **Inventors: BOT, Adrian, I.**; 3090 Franklin Canyon Drive, Beverly Hills, CA 90210 (US). **BUDKA, Justin**; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, CA 90404 (US). **CHOU, Szu-Ting**; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, CA 90404 (US). **MILLETTI, Francesca**; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, CA 90404 (US). **PLAKS, Vicki**; 1138 12th Street,


Apt. 8, Santa Monica, CA 90403 (US). **ROSSI, John, M.**; 1427 Ramona Drive, Newbury Park, CA 91320 (US).

- (74) **Agent: LOPEZ, Miguel, A.** et al.; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, CA 90404 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

- (54) **Title:** T CELL THERAPY



- (57) **Abstract:** The disclosure relates to methods of diagnosis and prognosis, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*